33 related articles for article (PubMed ID: 11848470)
1. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
Gao X; McDermott DF; Michaelson MD
Oncologist; 2019 Jun; 24(6):725-727. PubMed ID: 31036769
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Fraveto A; Cardinale V; Bragazzi MC; Giuliante F; De Rose AM; Grazi GL; Napoletano C; Semeraro R; Lustri AM; Costantini D; Nevi L; Di Matteo S; Renzi A; Carpino G; Gaudio E; Alvaro D
PLoS One; 2015; 10(11):e0142124. PubMed ID: 26571380
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
Singh R; Zhang Y; Pastan I; Kreitman RJ
Clin Cancer Res; 2012 Jan; 18(1):152-60. PubMed ID: 22068660
[TBL] [Abstract][Full Text] [Related]
4. An experimental model of tumor dormancy therapy for advanced head and neck carcinoma.
Nishimura G; Yanoma S; Satake K; Ikeda Y; Taguchi T; Nakamura Y; Hirose F; Tsukuda M
Jpn J Cancer Res; 2000 Nov; 91(11):1199-203. PubMed ID: 11092987
[TBL] [Abstract][Full Text] [Related]
5. Highly Stable Tetra-Phenolato Titanium(IV) Agent Formulated into Nanoparticles Demonstrates Anti-Tumoral Activity and Selectivity.
Meker S; Braitbard O; Margulis-Goshen K; Magdassi S; Hochman J; Tshuva EY
Molecules; 2015 Oct; 20(10):18526-38. PubMed ID: 26473816
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts.
Tanino H; Kubota T; Yamada Y; Koh J; Kase S; Furukawa T; Kuo TH; Saikawa Y; Kitajima M; Naito Y
Jpn J Cancer Res; 1995 Aug; 86(8):770-5. PubMed ID: 7559101
[TBL] [Abstract][Full Text] [Related]
7. Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin.
Watanabe Y; Aoi A; Horie S; Tomita N; Mori S; Morikawa H; Matsumura Y; Vassaux G; Kodama T
Cancer Sci; 2008 Dec; 99(12):2525-31. PubMed ID: 19018767
[TBL] [Abstract][Full Text] [Related]
8. Synergistic and Additive Effects of Herbal Medicines in Combination with Chemotherapeutics: A Scoping Review.
Jung T; Cheon C
Integr Cancer Ther; 2024; 23():15347354241259416. PubMed ID: 38867515
[TBL] [Abstract][Full Text] [Related]
9. Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.
Parise RA; Anyang BN; Eiseman JL; Egorin MJ; Covey JM; Beumer JH
Cancer Chemother Pharmacol; 2013 Jan; 71(1):73-83. PubMed ID: 23053264
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).
Parise RA; Eiseman JL; Clausen DM; Kicielinski KP; Hershberger PA; Egorin MJ; Beumer JH
Cancer Chemother Pharmacol; 2015 Sep; 76(3):537-46. PubMed ID: 26193988
[TBL] [Abstract][Full Text] [Related]
11. Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism.
Loganathan S; Kanteti R; Siddiqui SS; El-Hashani E; Tretiakova M; Vigneswaran H; Cervantes G; Natarajan V; Husain AN; Vokes EE; Kindler HL; Salgia R
J Carcinog; 2011 Mar; 10():4. PubMed ID: 21383961
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.
Benhadji KA; Serova M; Ghoul A; Cvitkovic E; Le Tourneau C; Ogbourne SM; Lokiec F; Calvo F; Hammel P; Faivre S; Raymond E
Br J Cancer; 2008 Dec; 99(11):1808-15. PubMed ID: 19034280
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
Teicher BA; Menon K; Alvarez E; Liu P; Shih C; Faul MM
In Vivo; 2001; 15(3):185-93. PubMed ID: 11491013
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
Cancer Chemother Pharmacol; 2001 Dec; 48(6):473-80. PubMed ID: 11800028
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for renal cell cancer: what are possible options?
Santos N; Wenger JB; Havre P; Liu Y; Dagan R; Imanirad I; Ivey AM; Zlotecki RA; Algood CB; Gilbert SM; Allegra CJ; Okunieff P; Vieweg J; Dang NH; Luesch H; Dang LH
Oncology; 2011; 81(3-4):220-9. PubMed ID: 22085914
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in metastatic renal cell carcinoma.
Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
